LINGO binding molecules and pharmaceutical use thereof
AssigneeNovartis AG
InventorsAdrian Walmsley, William Leonard Wishart, Marta Cortes-Cros, Josef Prassler, Ingo Klagge
Life of this patent
Estimating the term…
Loading patent…
AssigneeNovartis AG
InventorsAdrian Walmsley, William Leonard Wishart, Marta Cortes-Cros, Josef Prassler, Ingo Klagge
Estimating the term…
The present invention provides a binding molecule which is capable of binding to the rat, cynomolgus monkey and human LINGO polypeptide, and a polynucleotide encoding the binding molecule. The invention also provides an expression vector comprising the polynucleotide, an expression system comprising a polynucleotide capable of producing a binding molecule, as well as an isolated host cell comprising the expression system for producing the binding molecule. The invention also provides for compositions comprising the LINGO binding molecules and the use of binding molecule compositions as a pharmaceutical, especially in the treatment to promote axonal regeneration/plasticity. The invention further provides for a method of treatment of diseases associated with axonal degeneration and demyelination.
A monoclonal antibody, or antigen binding fragment thereof, which is capable of binding to a LINGO-1 protein having an amino acid sequence of SEQ ID NO:
Dependencies are inferred from the claim text.